Joseph Francis Krzyzaniak

This inventor holds 16 USPTO granted patents and 2 published patent applications, plus 18 CIPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Pfizer Corporation, Warner-Lambert Company. Active years: 2003-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joseph Francis Krzyzaniak. Retrieved from https://idiyas.com/inventor/joseph-francis-krzyzaniak

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 2)

% Patents Active = 75.0

CIPO Patents = 18 (Patent Applications = 1)

Average Co-Inventor Count = 2.6

ph-index = 4

Forward Citations = 76(Granted Patents)

Company Filing History:

Warner-Lambert Company

patents

Years Active: 2003-2018

Loading Chart...

Areas of Expertise:

Pharmaceuticals

Salt Forms

Crystalline Structures

Dihydroxy Compounds

Fluorophenyl Derivatives

Pyrrole Compounds

Calcium Salts

Phenylamino Carbonyls

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9908850 - Salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-hepatonic acid (2018-03-06),

2. 9637449 - Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic-acid (2017-05-02),

3. 9481647 - Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-Phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (2016-11-01),

4. 9309195 - Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-hepatanoic acid (2016-04-12),

5. 9199932 - Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (2015-12-01),

6. 9073852 - Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid (2015-07-07),

7. 8895758 - Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-Dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (2014-11-25),

8. 8822703 - Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4[phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid (2014-09-02),

9. 8552207 - Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid (2013-10-08),

10. 8236966 - Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, alpha-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid (2012-08-07),

11. 8026376 - Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacid calcium salt (2:1) (2011-09-27),

12. 7875731 - Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid (2011-01-25),

13. 7534810 - Salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid (2009-05-19),

14. 7144915 - Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (2006-12-05),

15. 6683106 - N-(indole-2-carbonyl)-b-alaninamide crystal forms (2004-01-27),

Title: Joseph Francis Krzyzaniak: A Pioneer in Pharmaceutical Innovations

Introduction: Joseph Francis Krzyzaniak, a prolific inventor based in Pawcatuck, Connecticut, has made significant contributions to the field of pharmaceuticals, holding a remarkable total of 16 patents. His innovative work primarily focuses on novel pharmaceutical compounds and their applications in treating critical health issues.

Latest Patents: Among his latest patents, Krzyzaniak developed unique salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid. These novel salt forms are characterized by their X-ray powder diffraction patterns and solid-state NMR spectra. Krzyzaniak’s inventions are intended for pharmaceutical compositions aimed at treating a variety of conditions, including hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Career Highlights: Joseph Krzyzaniak has worked with leading companies in the pharmaceutical industry, including Pfizer Corporation and Warner-Lambert Company. His career is marked by a commitment to innovation and improving health outcomes through scientific advancements.

Collaborations: Throughout his career, Krzyzaniak has collaborated with notable professionals in his field, including Jason Albert Leonard and Zheng Jane Li. These partnerships have fostered an environment of innovation and creativity, contributing to his successful patent portfolio.

Conclusion: Joseph Francis Krzyzaniak exemplifies the spirit of innovation in the pharmaceutical industry. His 16 patents reflect a dedication to developing effective treatments for various health issues, showcasing his role as a significant contributor to modern medicine. As he continues to forge paths in pharmaceutical research, the impact of his work remains substantial.

Profile summary based on public USPTO records.